Wedbush analyst Liana Moussatos maintained a Buy rating on Ascendis Pharma (ASND) today and set a price target of $219. The company’s shares opened today at $118.61.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.4% and a 39.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ascendis Pharma with a $158.33 average price target, which is a 33.5% upside from current levels. In a report issued on March 25, Evercore ISI also initiated coverage with a Buy rating on the stock with a $180 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $131.76 and a one-year low of $53.21. Currently, Ascendis Pharma has an average volume of 400.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market.
